Target intelligence / Profile preview

D-alanyl-D-alanine-containing cell wall precursor

Molecular classification
Other (cell wall biosynthetic intermediate), Peptidoglycan precursor
01

Overview

D-alanyl-D-alanine-containing cell wall precursors are essential intermediates in the biosynthesis of bacterial peptidoglycan. These precursors consist of a pentapeptide chain ending with a terminal D-alanyl-D-alanine sequence attached to N-acetylmuramic acid within the growing peptidoglycan structure. The presence of this dipeptide is critical for proper cross-linking during cell wall assembly—a process catalyzed by transpeptidase enzymes (penicillin-binding proteins). Glycopeptide antibiotics such as vancomycin exert their antibacterial effect by binding specifically to this terminal motif on nascent peptidoglycan chains. This interaction blocks further extension and cross-linking steps required for mature cell wall formation, ultimately resulting in bacterial death due to loss of structural integrity. Resistance mechanisms include modification or replacement of the terminal dipeptide (e.g., substitution with D-lactate), which reduces antibiotic binding affinity and confers drug resistance[2][3][5].

Other names
D-Ala-D-Ala-ended peptidoglycan precursorD-Ala-D-Ala-terminated Lipid IIpeptidoglycan pentapeptide precursorterminal D-alanyl-D-alanine motif
02

Mechanism of action

Inhibition of cell wall synthesis by binding to the terminal D-Ala-D-Ala motif, preventing cross-linking and polymerization of peptidoglycan strands[2]

03

Biological functions

Cell wall biosynthesisMaintenance of bacterial cell shape and rigidityBacterial growth and division
04

Disease associations

Infection (target in antibacterial therapy)
05

Safety considerations

Not a direct safety concern for humans; however, resistance can arise if bacteria alter the target site (e.g., replacing D-Ala-D-Ala with D-Ala-D-Lac), leading to therapeutic failure[2]
06

Interacting drugs

Vancomycin[2]

1 more in the full profile.

07

Biomarkers

Presence or abundance may indicate susceptibility to glycopeptide antibiotics such as vancomycin[2]

Beyond the preview

Go deeper on D-alanyl-D-alanine-containing cell wall precursor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine-containing cell wall precursor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call